Sort

Search

Search Bar
01/09/2025 DESCRIPTION OF SEXUAL AND REPRODUCTIVE HEALTH IN A POPULATION IN A SITUATION OF HIGH SOCIAL VULNERABILITY
Valmayor, S, Roel, E, Gil, S, Gabaró, S, Salobral, R. DESCRIPTION OF SEXUAL AND REPRODUCTIVE HEALTH IN A POPULATION IN A SITUATION OF HIGH SOCIAL VULNERABILITY. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025 EIRA, HEALTH PROTECTION INFORMATION SYSTEM
Marín, PG, Balaguero, NB, Baró, MAB, Gutiérrez, AG, Tudela, SP, Ramon, MR, Macía, VT, Muñoz, NV. EIRA, HEALTH PROTECTION INFORMATION SYSTEM. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025 HEAT-RELATED MORTALITY SURVEILLANCE IN THE CITY OF BARCELONA
Oliveras, L, Marí-Dell'Olmo, M, Quijal-Zamorano, M, Gómez-Gutiérrez, A. HEAT-RELATED MORTALITY SURVEILLANCE IN THE CITY OF BARCELONA. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025 EVALUATION OF THE SEXUAL AND REPRODUCTIVE HEALTH PROGRAM, SIRIAN, WITH A POPULATION IN A SITUATION OF HIGH SOCIAL VULNERABILITY
Valmayor, S, Roel, E, Gabarró, S, Gil, S, Salobral, R. EVALUATION OF THE SEXUAL AND REPRODUCTIVE HEALTH PROGRAM, SIRIAN, WITH A POPULATION IN A SITUATION OF HIGH SOCIAL VULNERABILITY. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025 Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series
Mateu-Arrom, L, Martin, R, Expósito-Serrano, V, Alvarez-Abella, A, Serra-Baldrich, E, Spertino, J. Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.05.022. PMID:40480489. IF:(Q/D).
01/09/2025 Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups
Feldman, SR, Sanz, LP, Girolomoni, G, Jo, SJ, Jung, H, Jung, J. Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).